CurrentBody Skin LED Face Mask Review: An Effective Tool For Skin Renewal
I'm not entirely sure when my skin switched over from springy and glowy to creased, splotchy and tired, but I'm officially there. As a result, I live in search of unicorn of facial tools—ones that makes me look like I am wearing a permanent filter in real life without having to apply seven layers of undetectable foundation. Over the course of weeks, I tested the top-rated CurrentBody LED Light Therapy Face Mask Series 2, which uses red, near-infrared and deep near-infrared light to reduce wrinkles, increase skin plumpness and boost collagen production. While it can take up to eight weeks to see more significant results, I've already noticed a glow and a reduction in overall skin redness.
In our testing, we found the CurrentBody Skin LED Light Therapy Face Mask Series 2 helped with ... More overall glowiness and evening tone.
At $470, this product is an investment; still, it's far less expensive than costly in-office treatments, and far more convenient because I can wear it while in bed or on the couch. It requires 10 minutes of use three to five times per week. After using it for two weeks (and ongoing testing), I can already see noticeable results. If you're looking to improve skin dullness, decrease redness from conditions like acne or rosacea, or minimize the look of smile lines and crow's feet, the CurrentBody LED face mask is a worthwhile pick.
Amazon
Light modes: Red, near-infrared and deep near-infrared | Skin concerns: Fine lines, wrinkles, hyperpigmentation, dullness | Wireless: Yes (with connected controller) | Number of LEDs: 263 | Usage: 10 minutes, three to five times per weekBest for:
Skip if:
This FDA-cleared device is wireless and powered by a rechargeable controller, which is slightly smaller than the length of a smartphone. You wear it for pre-programmed 10-minute treatments from three to five times per week. 'LED mask therapy is best suited for skin concerns related to inflammation, healing and aging,' says board-certified dermatologist Dr. Rhonda Q. Klein at Modern Dermatology. The CurrentBody mask works to brighten the skin, reduce the appearance of fine lines, improve texture and tone, decrease redness, and enhance collagen production. It features 236 LED lights and is comprised of red (633nm), near-infrared (830nm) and deep near-infrared (1072nm) wavelength bulbs. Red light targets fine lines and wrinkles, while also increasing collagen production. Near-infrared light is said to energize cells, firming, tightening and brightening the skin. Deep near-infrared light is designed to penetrate even deeper into the skin to help boost collagen production.
Compared to other LED devices on the market (our team evaluated the best LED face masks), the CurrentBody Series 2 LED face mask features a larger number of LED bulbs than many others, and it offers more focused treatment than the first-generation device. The mask is made from 'liquid' silicone, which is soft and comfortable to wear, and it flexes and molds easily to the face when the straps are tightened. This version has a new chin section to provide full face coverage—and to address an often-neglected treatment area. It also has 16 deeply penetrating deep near-infrared lights placed around the mask's eyes and mouth—an area of particular concern for many people—to help enhance results.
The CurrentBody LED Face Mask Series 2 features 263 LED lights in three different wavelengths—red, ... More near-infrared and deep near-infrared.
One thing that makes LED masks a popular beauty device is their efficacy. According to the brand's eight-week clinical study, the CurrentBody LED face mask treatments resulted in improvement of skin elasticity by 57% and a more radiant and youthful appearance. It reduced wrinkles by 30%, specifically causing forehead lines to appear softer. Skin tone brightness and skin firmness both significantly improved during that time, as did outer eye wrinkles and nasolabial folds, which decreased by more than 20%.
Setting up the CurrentBody LED face mask was straightforward. The instructions specified that the device should be charged for 4.5 hours (to reach a full charge) before use, which I did. Once it was ready to use, attaching the hook-and-loop closure straps to the mask took just a couple of minutes. The device has both a behind-the-head closure and a strap on top of the head for a secure fit.
Because mornings are typically rushed in my house, I preferred to use the CurrentBody device at night. I began by washing my face and patting it completely dry with a towel before putting on the mask for the ten-minute session while relaxing in bed. I liked that it's preset to turn off after the ten-minute treatment, so I didn't have to worry about setting a timer. It also has a clip-on controller and is otherwise cordless, which was nice in case I wanted to get up and move around.
The CurrentBody LED Face Mask Series 2 has elastic straps that fit behind and on top of your head to ... More keep the mask securely in place whether you're sitting or moving around.
During testing, the mask felt pleasantly warm on my face, but not hot. The included black eye inserts helped shield my eyes from LED light if I opened them, although I preferred to keep them shut while it was on. The mask had a lightweight feel, and it was easy to adjust the straps in the back so the whole thing wouldn't get jostled. However, the mask only sat flush with the skin on my forehead, around my eyes and on my upper cheeks; there was a slight gap between it and the skin on my lower jaw and chin. I have a more pronounced bridge on my nose, so the mask would become slightly uncomfortable and leave a small mark at the top of my nose by the end of the treatment, which would fade after a few minutes. After use, I wiped the inside of the mask with a slightly damp microfiber cloth, as I found that the mask attracted lint easily on both sides.
I wore the mask eight times over two weeks, and I will continue to do so for several months. Although it has only been a short period, I have noticed an overall brightening of my skin since wearing it. I'm hoping it will help decrease hyperpigmentation, even out my skin tone overall and reduce the small parentheses lines around my mouth.
In the relatively brief period that I've been using the mask, I've noticed overall skin brightening and a slight reduction in redness, meaning my face looks a little more even and filtered without needing to apply makeup. Even with limited use so far, I feel that this is a worthwhile investment, especially since it's easy to use and comfortable to wear. Additionally, editors on our team tested this CurrentBody LED face mask over more than a month. According to one tester, 'my skin tone appears a little more even, brighter, and some sun spots I have on my forehead seem to have faded.' Another says, 'I feel like my skin tone has evened out, and I feel a little more glowy and less like I have winter 'blah' skin.' Because clinical data also supports this device's efficacy, I feel confident that it will continue to produce visible results over time.
I'm a longtime magazine writer and editor who has extensive experience covering lifestyle topics. When it comes to beauty, I've written about and tested the best skincare for women over 50 and shampoos for color-treated hair and the best microcurrent devices, among many other stories. My first experience with red light therapy was when I tested the Therabody Theraface Pro, a versatile facial treatment tool that also has red light therapy. After a brief testing period using the CurrentBody LED Light Therapy Face Mask Series 2, I can already see a difference in my skin tone and brightness. I also reviewed testing data from our panel of testers to incorporate their experiences with the device.
This assignment was assigned and edited by deputy editor Jane Sung, who oversees the beauty and grooming vertical. She's covered beauty and lifestyle topics for over two decades and has produced numerous skincare stories and tested reviews like the best LED face masks roundup, best at-home laser hair removal devices and more. I also interviewed board-certified dermatologist Dr. Rhonda Q. Klein of Modern Dermatology for her expert insights.
The brand recommends using the device for 10 minutes a day from three to five times per week for optimal results. Of course, like with most beauty devices, consistent use is key.
Yes, the CurrentBody LED Light Therapy Face Mask Series 2 is FDA Cleared. This means that the Food and Drug Administration (FDA) has reviewed the device and deemed it safe and effective for use for its intended purpose. FDA approval typically requires additional, more rigorous testing.
'At-home LED devices can truly deliver results—but only if you're willing to commit to consistent, long-term use,' says dermatologist Dr. Rhonda Q. Klein. 'These treatments are proven effective when used properly and regularly.' To maximize your investment, Klein suggests looking for an FDA-cleared device with third-party clinical data supporting its claims. 'Focus on devices that use a variety of wavelengths, as this variety is most effective,' she says. 'The CurrentBody Series 2 includes 236 diodes for coverage all over the face and the LEDs emote the 3 most clinically studied wavelengths for anti-aging; red light (633nm), near-infrared (830nm) and deep near-infrared (1072nm) which delivers the treatment across the deep and more surface level layers of the skin.'
Benefits of using an LED face mask depend on continual, consistent use. 'It's not a set-it-and-forget-it treatment,' says Klein. 'This is a long-term ritual that needs to be used on an ongoing basis to achieve and then maintain results.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Weaver Nut Company recalls chocolate nonpareils over undeclared allergens
Multiple batches of chocolate nonpareils produced by Weaver Nut Company, Inc. and sold across the U.S. have been recalled due to potential undeclared milk allergens, the Food and Drug Administration announced earlier this week. Six lots of semi-sweet chocolate with "Christmas Seeds" colored nonpareils, or small ball-shaped sprinkles, and 15 lots of semi-sweet chocolate with white nonpareils are included in the recall. The FDA said those with an allergy or severe sensitivity to milk run the risk of serious or life-threatening allergic reactions if they consume the impacted products listed below. 47518 - Nonpareil, Semi-Sweet Chocolate (Christmas Seeds)Lot #(s): 204206, 204207, 204208, 204209, 204212, 224225 D2645 - Nonpareils, Semi-Sweet Chocolate (White Seeds)Lot #(s) 204214-RL, 204214, 204215, 224221, 224222, 224223, 135215, 135216, 135217, 135220, 135221, 145204, 145205-1, 145207-1, 145210-1 No illnesses have been reported but the product was sold at various retail and grocery store outlets across the country, the FDA said. "Weaver Nut Company is working with the FDA and is taking all necessary steps to ensure the safety of its products," company spokesperson Angela Nolt said in the recall announcement. The issue was discovered after a wholesale customer made a complaint, according to the FDA. A following lab test later confirmed the presence of milk. Saturday Sessions: Grace Potter performs "Paris" Saturday Sessions: Grace Potter performs "Medicine" Saturday Sessions: Grace Potter performs "Before the Sky Falls"
Yahoo
2 hours ago
- Yahoo
Weaver Nut Company recalls chocolate nonpareils over undeclared allergens
Multiple batches of chocolate nonpareils produced by Weaver Nut Company, Inc. and sold across the U.S. have been recalled due to potential undeclared milk allergens, the Food and Drug Administration announced earlier this week. Six lots of semi-sweet chocolate with "Christmas Seeds" colored nonpareils, or small ball-shaped sprinkles, and 15 lots of semi-sweet chocolate with white nonpareils are included in the recall. The FDA said those with an allergy or severe sensitivity to milk run the risk of serious or life-threatening allergic reactions if they consume the impacted products listed below. 47518 - Nonpareil, Semi-Sweet Chocolate (Christmas Seeds)Lot #(s): 204206, 204207, 204208, 204209, 204212, 224225 D2645 - Nonpareils, Semi-Sweet Chocolate (White Seeds)Lot #(s) 204214-RL, 204214, 204215, 224221, 224222, 224223, 135215, 135216, 135217, 135220, 135221, 145204, 145205-1, 145207-1, 145210-1 No illnesses have been reported but the product was sold at various retail and grocery store outlets across the country, the FDA said. "Weaver Nut Company is working with the FDA and is taking all necessary steps to ensure the safety of its products," company spokesperson Angela Nolt said in the recall announcement. The issue was discovered after a wholesale customer made a complaint, according to the FDA. A following lab test later confirmed the presence of milk. Saturday Sessions: Grace Potter performs "Paris" Saturday Sessions: Grace Potter performs "Medicine" Saturday Sessions: Grace Potter performs "Before the Sky Falls"
Yahoo
8 hours ago
- Yahoo
Perspective Therapeutics Commences Recruitment for [212Pb]VMT-α-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial
[212Pb]VMT-α-NET Phase 1/2a study is advancing into Cohort 3 with a fixed administered dose that is up to 20% higher (6 mCi) than the dose administered to patients in Cohort 2 Dosimetry sub-study analysis presented at the Society of Nuclear Medicine & Molecular Imaging (SNMMI) 2025 Annual Meeting to advance utility of dosimetry in clinical development when considered with clinical data On track to submit further clinical updates to scientific congresses in 2H 2025, including longer safety follow-up on all patients who have received at least one treatment of [212Pb]VMT-α-NET and anti-tumor activities in patients dosed to date who have had the opportunity to receive at least one scan after their full treatment SEATTLE, June 21, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that alignment was reached with the U.S. Food and Drug Administration (FDA) to open the third dosing cohort (Cohort 3) of its ongoing Phase 1/2a clinical trial for [212Pb]VMT-α-NET in patients with unresectable or metastatic somatostatin receptor 2 (SSTR2)-positive neuroendocrine tumors (NETs) who have not received prior radiopharmaceutical therapies (RPT). "We are excited to start exploring a higher dose level of VMT-α-NET after successfully completing an interaction with the FDA that was agreed prior to commencement of this trial," commented Markus Puhlmann, Chief Medical Officer of Perspective. "We are encouraged by the overall clinical profile observed at the second dose level of VMT-α-NET—including evidence of anti-tumor activity and primarily low-grade adverse events—and we believe it is important to assess whether a higher dose could further improve the therapeutic profile. Meanwhile, we remain committed to engaging with the FDA to evaluate the clinical utility of dosimetry estimates and analyses in the development of our proprietary RPTs." Patients in Cohort 3 will receive up to four fixed administered doses of [212Pb]VMT-α-NET at 6 mCi every eight weeks if they weigh more than 60kg (133lb), or 100μCi/kg of body weight if they weigh less than or equal to 60kg. Observations of dose limiting toxicities (DLTs) in up to eight patients within 42 days of the first treatment cycle will be used to assess whether this cohort of patients have received maximum tolerated dose (MTD) or maximum feasible dose (MFD). Once a safety monitoring committee (SMC) has reviewed the data from these initial patients, it may recommend exploring alternative dosing and/or recruit more patients into Cohort 3. Perspective is notifying sites that Cohort 3 is now open for recruitment. Patients currently being evaluated for entry into the study will enroll into Cohort 3 if they qualify. Pending feedback from sites on operationalizing enrollment into Cohort 3, an update on pace of recruitment will be provided in due course. About [212Pb]VMT-α-NETPerspective designed [212Pb]VMT-α-NET to target and deliver 212Pb to tumor sites expressing SSTR2. The Company is conducting a multi-center, open-label, dose-escalation, dose-expansion study ( identifier NCT05636618) of [212Pb]VMT-α-NET in patients with unresectable or metastatic SSTR2-positive neuroendocrine tumors who have not received a prior RPT. Interim update with a data cut-off date of April 30, 2025 were reported in an oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in May 2025. Cohort 2 was reopened in August 2024. During 2H 2025, some of the 33 additional patients enrolled after the cohort reopened and through April 30, 2025 will have had the opportunity for at least 32 weeks of follow-up after their initial doses, sufficient time to receive at least one scan after their full treatment (up to four doses every eight weeks), if they receive all four doses of treatment per protocol. About Perspective Therapeutics, Therapeutics, Inc. is a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The Company is also developing complementary imaging diagnostics that incorporate the same targeting moieties, which provides the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity. The Company's melanoma (VMT01), neuroendocrine tumor (VMT-α-NET), and solid tumor (PSV359) programs are in Phase 1/2a imaging and therapy trials in the U.S. The Company is growing its regional network of drug product finishing facilities, enabled by its proprietary 212Pb generator, to deliver patient-ready products for clinical trials and commercial operations. For more information, please visit the Company's website at Safe Harbor StatementThis press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include statements concerning, among other things, the Company's ability to pioneer advanced treatments for cancers throughout the body; the Company's belief that it is on track to submit further clinical updates to scientific congresses in 2H 2025 and the planned content of such updates; the Company's ability to explore a higher dose level of VMT-α-NET; the Company's commitment to engage with the FDA to evaluate the clinical utility of dosimetry estimates and analyses in the development of its proprietary RPTs; the Company's expectation that patients currently being evaluated for entry into its VMT-α-NET study will enroll into Cohort 3 if they qualify; the ability of the Company's proprietary technology utilizing the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties; the Company's prediction that the use of complementary imaging diagnostics that incorporate the same targeting moieties provides the opportunity to personalize treatment and optimize patient outcomes; the Company's belief that its "theranostic" approach enables the ability to see a specific tumor and then treat it to potentially improve efficacy and minimize toxicity; the Company's ability to grow its regional network of drug product finishing facilities, enabled by its proprietary 212Pb generator, to deliver patient-ready products for clinical trials and commercial operations; and other statements that are not historical fact. These forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from the results described in or implied by the forward-looking statements. Certain factors that may cause the Company's actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC"), in the Company's other filings with the SEC, and in the Company's future reports to be filed with the SEC and available at Forward-looking statements contained in this news release are made as of this date. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Media and Investor Relations Contacts: Perspective Therapeutics IR:Annie J. Cheng, CFAir@ Russo Partners, LLCNic JohnsonPerspectiveIR@
